Treatment of Chronic Hepatitis B in HBsAg-Positive Pregnant Individuals with HBV DNA > 200,000 IU/mL
This protocol addresses a specific, high-risk scenario: pregnant individuals who are HBsAg-positive and carry a high HBV viral load, placing the fetus at elevated risk of perinatal hepatitis B acquisition.
Clinical Scenario
HBsAg-positive pregnant individuals with HBV DNA levels > 200,000 IU/mL, regardless of HBeAg status. The central concern is mother-to-child transmission (MTCT) of hepatitis B virus.
Treatment Goal
Reduction of maternal HBV DNA — viral suppression — to lower the risk of transmitting hepatitis B to the newborn at the time of delivery.
Approach (partial overview)
Antiviral prophylaxis is initiated at a defined point in the third trimester and continued through delivery. The full protocol specifies which agents are recommended, the evidence behind each, and what to do when a pregnant individual presents late — access the regimen below for the complete guidance.
References
DOI: 10.1097/HEP.0000000000001549
- Population: HBsAg-positive pregnant individuals with HBV DNA levels > 200,000 IU/mL
- For pregnant persons with HBV DNA levels greater than 200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD recommends initiating tenofovir disoproxil fumarate or tenofovir alafenamide at gestational week 28 to prevent mother-to-child transmission.
- Tenofovir disoproxil fumarate has a more extensive safety record in pregnancy than tenofovir alafenamide.
- For mothers with HBV DNA levels > 200,000 IU/mL who seek perinatal care later than week 28, TDF or TAF prophylaxis should still be initiated immediately to reduce the risk of MTCT.
- Prophylactic TDF therapy, initiated from the start of the third trimester (gestational week 28 onwards) until delivery, among pregnant persons with high viremia (> 200,000 IU/mL) effectively reduces maternal viremia and decreases the rate of MTCT.
View source ↗